IDEXX Laboratories Inc. said its second-quarter net income attributable to stockholders came to $125.7 million, an increase of 15.7% from $108.7 million in the year-earlier period.
EPS climbed 16.3% year over year to $1.43 from $1.23.
The S&P Global Market Intelligence consensus normalized EPS estimate for the quarter is $1.37.
The Westbrook, Maine-based medical-device maker's revenue rose 6.8% yearly to $620.1 million from $580.8 million. Research and development expenses also rose 9.3% on an annual basis to $32.3 million from $29.5 million.
IDEXX revised its outlook for the full year, with EPS in the range of $4.82 to $4.92, up from previous guidance in the range of $4.76 to $4.88.
Meanwhile, the company lowered its revenue forecast to $2.38 billion to $2.41 billion, compared to its prior outlook of $2.39 billion to $2.43 billion, to reflect the impact of updated foreign exchange estimates and operational refinements for the second quarter.
The S&P Global Market Intelligence consensus normalized EPS estimate for 2019 is $4.83.